Join
Live feed
·
PRReleasevia Quantisnow
Mirum Pharmaceuticals Inc. logo

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

ByQuantisnow·Wall Street's wire, on your screen.
MIRM· Mirum Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MIRM (Mirum Pharmaceuticals Inc.) and more on Quantisnow.